Stock Events

HLB Therapeutics. 

₩7,800
2
+₩0+0% Today

Statistics

Day High
7,950
Day Low
7,580
52W High
9,300
52W Low
2,840.58
Volume
1,481,701
Avg. Volume
1,766,725
Mkt Cap
194.58B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-97.68
-85.59
-73.5
-61.41
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 115450.KQ. It's not an investment recommendation.

About

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021. HLB Therapeutics Co.,Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.
Show more...
CEO
Mr. Doug Jang
Employees
91
Country
KR
ISIN
KR7115450009

Listings